4-(3-甲氧基苯基)苯胺 | 207287-79-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(3-甲氧基苯基)苯胺
• 中文别名: 3'-甲氧基-联苯-4-基胺；(3-甲氧基二苯-4-基)胺1HCL
• 英文名称: 3'-methoxy-[1,1'-biphenyl]-4-amine
• 英文别名: 4-amino-3'-methoxybiphenyl；4-(3-Methoxyphenyl)aniline
• CAS: 207287-79-4
• 化学式: C₁₃H₁₃NO
• mdl: MFCD07772428
• 分子量: 199.252
• InChiKey: OSWFIVFLDKOXQC-UHFFFAOYSA-N

物化性质

• 沸点：
  340.3±17.0 °C(Predicted)
• 密度：
  1.100±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2922299090

反应信息

• 作为反应物：
  描述：

  4-(3-甲氧基苯基)苯胺 在 palladium on activated charcoal 氢碘酸 、 氢气 、 碳酸氢钠 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 甲苯 为溶剂， 65.0 ℃ 、303.98 kPa 条件下， 反应 54.0h， 生成 Cyclohexyl-carbamic acid 4''''-amino-biphenyl-3-yl ester
  参考文献：
  名称：

  Cyclohexylcarbamic Acid 3‘- or 4‘-Substituted Biphenyl-3-yl Esters as Fatty Acid Amide Hydrolase Inhibitors:  Synthesis, Quantitative Structure−Activity Relationships, and Molecular Modeling Studies

  摘要：

  Fatty acid amide hydrolase (FAAH) is a promising target for modulating endocannabinoid and fatty acid ethanolamide signaling, which may have important therapeutic potential. We recently described a new class of O-arylcarbamate inhibitors of FAAH, including the cyclohexylcarbamic acid biphenyl-3-yl ester URB524 (half-maximal inhibitory concentration, IC50 = 63 nM), which have significant anxiolytic-like properties in rats. In the present study, by introducing a selected group of substituents at the meta and para positions of the distal phenyl ring of URB524, we have characterized structure-activity profiles for this series of compounds and shown that introduction of small polar groups in the meta position greatly improves inhibitory potency. Most potent in the series was the m-carbamoyl derivative URB597 (4i, IC50 = 4.6 nM). Furthermore, quantitative structure-activity relationship (QSAR) analysis of an extended set of meta-substituted derivatives revealed a negative correlation between potency and lipophilicity and suggested that small-sized substituents may undertake polar interactions with the binding pocket of the enzyme. Docking studies and molecular dynamics simulations, using the crystal structure of FAAH, indicated that the O-biphenyl scaffold of the carbamate inhibitors can be accommodated within a lipophilic region of the substrate-binding site, where their folded shape mimics the initial 10-12 carbon atoms of the arachidonyl moiety of anandamide (a natural FAAH substrate) and methyl arachidonyl fluorophosphonate (a nonselective FAAH inhibitor). Moreover, substituents at the meta position of the distal. phenyl ring can form hydrogen bonds with atoms located on the polar section of a narrow channel pointing toward the membrane-associated side of the enzyme. The structure-activity characterization reported here should help optimize the pharmacodynamic and pharmacokinetic properties of this class of compounds.

  DOI：

  10.1021/jm031140x
• 作为产物：
  描述：

  在 盐酸羟胺 作用下， 以 乙醇 、 水 为溶剂， 反应 24.0h， 生成 4-(3-甲氧基苯基)苯胺
  参考文献：
  名称：

  定向原位金属化方法。N，N-二烷基芳基邻氨基磺酸盐作为格氏试剂的新的定向金属化基团和交叉偶联伙伴。

  摘要：

  [反应：参见文本] 3的邻位金属化（RLi / THF / -93摄氏度），然后用各种亲电试剂淬火，构成了取代O-氨基磺酸芳基酯4a-k的新通用路线。O-氨基磺酸盐4e，4n-s和6a与Grignard试剂的Kumada-Corriu交叉偶联可得到联芳基9a-m，而Suzuki-Miyaura交叉使用2-halo和硼衍生物4h，4i和4k。苯并炔的偶合和生成导致萘酚7a和7b。报告了OSONEt（2）的相对金属化等级。

  DOI：

  10.1021/ol050393c

文献信息

• NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS
  申请人：MUTHUPPALANIAPPAN Meyyappan

  公开号：US20110275603A1

  公开（公告）日：2011-11-10

  The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.

  本发明提供了脱氢鸟苷酸脱氢酶抑制剂，其制备方法，含有它们的药物组合物以及治疗、预防和/或改善疾病或障碍的方法，其中已知抑制脱氢鸟苷酸脱氢酶具有益处效果。
• 三唑萘醌联芳环衍生物或三唑萘醌联芳杂环 衍生物及其制备方法和用途
  申请人：四川大学

  公开号：CN108467370B

  公开（公告）日：2021-11-23

  本发明属于化学医药领域，具体涉及抗恶性肿瘤、抗急性白血病和关节炎、多发性硬化症和免疫排斥反应小分子及其制备方法和用途。本发明要解决的技术问题是目前临床上二氢乳酸脱氢酶抑制剂小分子上市药物和及其现有其他药理模型的化合物毒副作用大的缺点。本发明解决上述技术问题的方案是提供了一种三唑萘醌联芳环衍生物或三唑萘醌联芳杂环衍生物，该衍生物主要是与三唑连接不同联芳环或联芳杂环，发明提供的化合物具有抗恶性肿瘤活性高且毒副作用低，并能克服临床耐药的优点，在针对治疗恶性肿瘤药物开发上具有很大的价值。
• Fingerprints of Singlet and Triplet Phenyl Cations
  作者：Micha Slegt、Hermen S. Overkleeft、Gerrit Lodder

  DOI：10.1002/ejoc.200700339

  日期：2007.11

  The photolyses of seven phenyl cation precursors in acetonitrile in the presence of anisole resulted in four distinct product patterns. These patterns are due to the chemoselective and regioselective chemistry of various phenyl cation isomers. This spin-selective chemistry provides a tool with which to fingerprint the singlet/triplet nature of any phenyl cation.(© Wiley-VCH Verlag GmbH & Co. KGaA,

  在苯甲醚存在下，七种苯基阳离子前体在乙腈中的光解产生四种不同的产物模式。这些模式归因于各种苯基阳离子异构体的化学选择性和区域选择性化学。这种自旋选择性化学提供了一种工具，可用于识别任何苯基阳离子的单线态/三线态性质。（© Wiley-VCH Verlag GmbH & Co. KGaA，69451 Weinheim，德国，2007）
• <i>N</i>-Heterocyclic Carbene Coordinated Heterogeneous Pd Nanoparticles as Catalysts for Suzuki–Miyaura Coupling
  作者：Hyemin Min、Hiroyuki Miyamura、Shū Kobayashi

  DOI：10.1246/cl.160369

  日期：2016.7.5

  Palladium nanoparticle (Pd NP) catalysts immobilized in a polymer with an N-heterocyclic carbene (NHC) moiety (PICB-NHC-Pd) have been developed, wherein the NHC moiety plays dual roles as a crosslinker and a ligand to activate the Pd NPs. The presence of both Pd NPs and NHC was confirmed by STEM/EDS and SR-MAS NMR analyses, respectively. This PICB-NHC-Pd catalyst showed excellent activity in the Suzuki–Miyaura

  已开发出固定在具有 N-杂环卡宾 (NHC) 部分 (PICB-NHC-Pd) 的聚合物中的钯纳米颗粒 (Pd NP) 催化剂，其中 NHC 部分起着交联剂和配体的双重作用以激活 Pd NP . 分别通过 STEM/EDS 和 SR-MAS NMR 分析证实了 Pd NPs 和 NHC 的存在。这种 PICB-NHC-Pd 催化剂在 Suzuki-Miyaura 偶联反应中表现出优异的活性，而不会浸出 Pd。在克级合成中获得了优异的结果，并且在不损失催化剂活性的情况下完成了催化剂回收/再利用实验。
• [EN] COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS<br/>[FR] COMPOSÉS UTILES DANS LE TRAITEMENT DE TROUBLES ASSOCIÉS À RAS MUTANT
  申请人：UNIV OXFORD INNOVATION LTD

  公开号：WO2019234405A1

  公开（公告）日：2019-12-12

  The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.

  本发明涉及式I所定义的化合物，以及它们的盐和溶剂化物。（I）本发明还涉及包含式（I）化合物的药物组合物，以及式（I）化合物用于治疗增殖性疾病，如癌症，以及其它涉及抑制RAS效应蛋白-蛋白相互作用的疾病或状况。